Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Upatinib is an oral Janus kinase (JAK) 1 selective inhibitor and a disease modifying antirheumatic agent. Upatinib is used to treat rheumatoid arthritis to slow disease progression. Chemicalbook rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage, and bone destruction, resulting in comorbidities.